title: Effect of combined dexamethasone/lenalidomide therapy on NK cell-receptor levels in myeloma patients.
authors.forename: Clive R
authors.initials: CR
authors.lastname: Carter
authors.forename: Sylvia
authors.initials: S
authors.lastname: Feyler
authors.forename: Natuley
authors.initials: N
authors.lastname: Smalle
authors.forename: Gina B
authors.initials: GB
authors.lastname: Scott
authors.forename: Christopher
authors.initials: C
authors.lastname: Parrish
authors.forename: Katherine
authors.initials: K
authors.lastname: Cullen
authors.forename: Charlotte
authors.initials: C
authors.lastname: Kallmeyer
authors.forename: Philip M
authors.initials: PM
authors.lastname: Wood
authors.forename: Gordon
authors.initials: G
authors.lastname: Cook
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D003907:Dexamethasone / Q000494:pharmacology*; D019008:Drug Resistance, Neoplasm; D006801:Humans; D007694:Killer Cells, Natural / Q000502:physiology*; D009101:Multiple Myeloma / Q000188:drug therapy*; D013792:Thalidomide / Q000031:analogs & derivatives*
chemical_list: D000970:Antineoplastic Agents; D013792:Thalidomide; D003907:Dexamethasone